Through
4/26
Cancer Research
Blood test identifies more treatable cancer mutations than biopsies alone
Blood test identifies more treatable cancer mutations than biopsies alone
A new study shows patients with treatable mutations identified by liquid biopsies rather than tissue biopsies also largely respond to therapy.
Immune cells involved in triple-negative breast cancer could offer future therapeutic target
Immune cells involved in triple-negative breast cancer could offer future therapeutic target
New research led by Rumela Chakrabarti reveals how immune cells called myeloid-derived immunosuppressor cells contribute to the progression of triple-negative breast cancer, a particularly aggressive cancer. Pairing chemotherapy with a drug that blocks these cells may one day help stem its growth.
‘Cancer in all forms is our enemy’
‘Cancer in all forms is our enemy’
Robert H. Vonderheide, the Abramson Cancer Center director, talks innovation, discoveries, FDA approvals, and how to deliver top-of-the-line cancer care.
Cutting-edge science moves to the clinic to help ‘our furry friends’ fight cancer
Cutting-edge science moves to the clinic to help ‘our furry friends’ fight cancer
A year after its launch, the Penn Vet Cancer Center is solidifying the translational science pipeline, connecting basic scientists to the clinic and vice versa, to transform veterinary cancer care.
Discovering a single cell that leads to relapse
Discovering a single cell that leads to relapse
Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia.
DNA vaccine leads to immune responses in HPV-related head and neck cancer
DNA vaccine leads to immune responses in HPV-related head and neck cancer
Researchers from the Abramson Cancer Center find immunotherapy approach can help T cells infiltrate tumors.
CAR T cell therapy receives approval for use across European Union
CAR T cell therapy receives approval for use across European Union
The European Commission has approved a personalized cellular therapy developed at the Abramson Cancer Center, making it the first CAR T cell therapy permitted for use in the European Union in two distinct indications.
Penn Medicine’s Carl June receives 2018 Albany Prize
Penn Medicine’s Carl June receives 2018 Albany Prize
Carl June, a gene therapy pioneer at the Abramson Cancer Center, will receive the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.
Drugs in development for cancer may also fight brain diseases, including ALS
Drugs in development for cancer may also fight brain diseases, including ALS
In a study done by researchers at the Perelman School of Medicine and the School of Arts and Sciences, PARP inhibitors, which are used for fighting cancer, can be useful for the treatment and prevention of brain disorders such as ALS.
Cancer cells send out ‘drones’ to battle the immune system from afar
Cancer cells send out ‘drones’ to battle the immune system from afar
Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition, but only for some patients. Researchers uncovered a novel mechanism by which tumors suppress the immune system, raising the possibility that a straightforward blood test could predict which patients could respond to immunotherapy.
In the News
CNN
There’s still no standard test to detect pancreatic cancer early. Scientists are working to change that
A 2020 study from the Perelman School of Medicine found that a blood test to screen for certain biomarkers associated with pancreatic cancer was 92% accurate in its ability to detect disease.
FULL STORY →
Associated Press
A new strategy to attack aggressive brain cancer shrank tumors in two early tests
A clinical trial led by Stephen Bagley of the Perelman School of Medicine suggests that targeting two associated proteins with CAR T cell therapy could be a viable strategy for shrinking brain tumors.
FULL STORY →
Philadelphia Inquirer
Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people
A trial led by Susan Domchek of the Perelman School of Medicine could use a preventive vaccine to protect people with a BRCA gene mutation from cancer.
FULL STORY →
Philadelphia Inquirer
UPenn scientists among those developing vaccines that arm the immune system to fight cancer
Penn Medicine researchers like Nobel laureate Drew Weissman are leading efforts to develop a vaccine that prevents cancer, with remarks from Susan Domchek of the Basser Center for BRCA and Robert H. Vonderheide of the Abramson Cancer Center.
FULL STORY →
Psychology Today
AI detects cancers and immunotherapy biomarker
Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy.
FULL STORY →
Philadelphia Inquirer
Penn started giving cancer patients free rides to appointments. It helped reduce no-shows and increase clinical trial enrollment
The Abramson Cancer Center is attempting to address one of the most common challenges cancer patients face: lack of transportation to critically important appointments. Robert Vonderheide and Carmen Guerra of the Perelman School of Medicine are quoted on the Ride Health initiative.
FULL STORY →